Blue Venture Funds — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
ExAI develops technology for early cancer detection, diagnosis, and management.
AI & Machine LearningBiotechDigital HealthMedical DevicesPalo Alto, US
Patrick A. Arensdorf(Executive Officer, Director)
BoardHani Goodarzi(Director)inMichael Pellini(Director)Alexander Parker(Director)
Co-investorsAmplify PartnersS32Sandbox Industries
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)inShriram Raghunathan(Executive Officer, Director)
BoardChau Khuong(Director)inAllan May(Director)Mudit Jain(Director)inTracy Pappas(Director)in
Co-investorsAngelini VenturesJoyance PartnersOrbiMedTreo Ventures, LlcZühlke VenturesBridge Bank+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.












